Younossi ZM - Search Results

1

Opportunities and challenges following approval of resmetirom for MASH liver disease.

Lazarus JV, Ivancovsky Wajcman D, Mark HE, Younossi ZM, Kopka CJ, Cohen N, Bansal MB, Betel M, Brennan PN. Lazarus JV, et al. Among authors: younossi zm. Nat Med. 2024 Apr 19. doi: 10.1038/s41591-024-02958-z. Online ahead of print. Nat Med. 2024. PMID: 38641752 No abstract available.

2

Severe, Persistent, Disruptive Fatigue Post-SARS-CoV-2 Disproportionately Affects Young Women.

Price JK, de Avila L, Stepanova M, Weinstein AA, Pham H, Keo W, Racila A, Gerber S, Lam BP, Gerber LH, Younossi ZM. Price JK, et al. Among authors: younossi zm. Int J Gen Med. 2023 Sep 27;16:4393-4404. doi: 10.2147/IJGM.S423910. eCollection 2023. Int J Gen Med. 2023. PMID: 37789881 Free PMC article.

3

Can Frequent Toothbrushing Reduce the Risk of Cirrhosis among Patients with Nonalcoholic Fatty Liver Disease? Hints from a Registry-Based Study.

Keklikkiran C, Stepanova M, Younossi Z, Yilmaz Y. Keklikkiran C, et al. Dig Dis. 2023;41(6):932-937. doi: 10.1159/000531981. Epub 2023 Jul 26. Dig Dis. 2023. PMID: 37494892

4

The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD).

Henry L, Paik JM, Younossi ZM. Henry L, et al. Among authors: younossi zm. J Hepatol. 2024 May 22:S0168-8278(24)00359-3. doi: 10.1016/j.jhep.2024.05.024. Online ahead of print. J Hepatol. 2024. PMID: 38789012 No abstract available.

5

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials.

Zannad F, Sanyal AJ, Butler J, Ferreira JP, Girerd N, Miller V, Pandey A, Parikh CR, Ratziu V, Younossi ZM, Harrison SA. Zannad F, et al. Among authors: younossi zm. J Intern Med. 2024 May 13. doi: 10.1111/joim.13793. Online ahead of print. J Intern Med. 2024. PMID: 38738988 Review.

6

Development of a Primary Biliary Cholangitis-specific Version of Chronic Liver Disease Questionnaire: CLDQ-PBC.

Younossi ZM, Stepanova M, Younossi I, Racila A. Younossi ZM, et al. Clin Transl Gastroenterol. 2024 May 13. doi: 10.14309/ctg.0000000000000709. Online ahead of print. Clin Transl Gastroenterol. 2024. PMID: 38738764

7

Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis.

Younossi ZM, Mangla KK, Berentzen TL, Grau K, Kjær MS, Ladelund S, Nitze LM, Coolbaugh C, Hsu CY, Hagström H. Younossi ZM, et al. Hepatol Commun. 2024 May 10;8(6):e0423. doi: 10.1097/HC9.0000000000000423. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38727678 Free PMC article.

8

Assessment of fatigue and its impact in chronic liver disease.

Younossi ZM, Kremer AE, Swain MG, Jones D, Bowlus C, Trauner M, Henry L, Gerber L. Younossi ZM, et al. J Hepatol. 2024 Apr 24:S0168-8278(24)00276-9. doi: 10.1016/j.jhep.2024.04.008. Online ahead of print. J Hepatol. 2024. PMID: 38670320

9

Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt.

Alqahtani SA, Yilmaz Y, El-Kassas M, Alswat K, Sanai F, AlZahrani M, Abaalkhail F, AlShaikh M, Al-Hamoudi WK, Nader F, Stepanova M, Younossi ZM; Global NASH Council. Alqahtani SA, et al. Among authors: younossi zm. J Viral Hepat. 2024 Jun;31(6):300-308. doi: 10.1111/jvh.13935. Epub 2024 Apr 15. J Viral Hepat. 2024. PMID: 38622910

10

Epidemiology of NAFLD - Focus on diabetes.

Younossi ZM, Henry L. Younossi ZM, et al. Diabetes Res Clin Pract. 2024 Apr;210:111648. doi: 10.1016/j.diabres.2024.111648. Epub 2024 Apr 2. Diabetes Res Clin Pract. 2024. PMID: 38569945

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

585 results

Search Page